AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

XTL Biopharmaceuticals Ltd.

Legal Proceedings Report Jul 18, 2005

7116_rns_2005-07-18_3f8b413e-b036-4788-9c2e-5309dcb1c9c0.htm

Legal Proceedings Report

Open in Viewer

Opens in native device viewer



C004 אקס טי אל ביופרמסוטיקלס בע"מ 2
Public X T L BIOPHARMACEUTICALS LTD
4312 Corporation no: 520039470
Stock Exchange/Market: אקס טי אל
1996
352 Hasapir 3 , Nes Ziona 76100 , ,
Tel: 08-9304444 , Fax: 08-9304445
E.mail address: [email protected] Date of transmission: 18/07/2005
Time of broadcast: 10:57 10:56:36
Reference: 2005-02-054570
Israel Securities Authority Tel Aviv Stock Exchange
www.isa.gov.il www.tase.co.il

Immediate report on other matterDon't use this form if there is more adequate one

XTLbio Receives Fast Track Designation for Hepatitis C Therapy from US FDA
Attached file PRESS.pdf
References of previous documents relating to this matter(the reference does not constitute incorporation by reference):
Previous name of reporting entity: XENOGRAFT TECHNOLOGIES LTD
Date of revision of form structure: 11/07/2005
- - -
Name of the Signatory : Burgin Jonathan , , Position of Signatory in the reporting corporation: Chief Financial Officer
Hasapir Telephone: 08-9304440 , Facsimile: 08-9300659 , E-mail: [email protected]

Talk to a Data Expert

Have a question? We'll get back to you promptly.